viernes, 4 de agosto de 2017

BMC Biotechnology | Home page

BMC Biotechnology | Home page

Biomed Central

BMC Biotechnology



Call for papers: Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy

BMC Biotechnology is currently accepting submissions to a thematic series entitled ' Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy'. 
Chimeric antigen receptor (CAR) T cells therapies, as a cancer immunotherapy, have provided significant benefit in treating cancer.
To present the recent advances in the theory and application of CAR immunotherapy, we invite you and/or members of your research team to provide a manuscript for this thematic series.
Your submission could take the form of original research, review, or commentary.
Deadline for submission to the collection: 30th June 2018
New Content Item

Articles


No hay comentarios:

Publicar un comentario